SGLT-1 inhibitors reduce intestinal glucose absorption, leading to lower glucose peaks. SGLT-2 inhibitors reduce reabsorption of sodium and glucose from the proximal tubules also resulting in lower postprandial hyperglycemia. Here, SLC5A2 is linked to Hyperglycemia.